--- title: "Analyst Reiterates Buy on Prothena, Maintaining $30 Price Target on CYTOPE and PRX012-TfR Platform Strength" type: "News" locale: "en" url: "https://longbridge.com/en/news/285764374.md" description: "H.C. Wainwright analyst Andrew Fein has reiterated a Buy rating on Prothena (PRTA) with a $30 price target, citing the strength of its CYTOPE and PRX012-TfR platforms. He highlights CYTOPE's preclinical evidence in ALS models and its modular design, which can be adapted for various applications. Fein also notes the competitive positioning of PRX012-TfR in Alzheimer's treatment. Citizens JMP has similarly maintained a Buy rating with a $20 price target. Fein is recognized as a 5-star analyst with a strong track record in the Healthcare sector." datetime: "2026-05-08T18:46:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285764374.md) - [en](https://longbridge.com/en/news/285764374.md) - [zh-HK](https://longbridge.com/zh-HK/news/285764374.md) --- # Analyst Reiterates Buy on Prothena, Maintaining $30 Price Target on CYTOPE and PRX012-TfR Platform Strength H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on PRTA stock, giving a Buy rating today. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Andrew Fein has given his Buy rating due to a combination of factors centered on Prothena’s advancing CYTOPE and PRX012-TfR platforms, which he views as the core value drivers in the company’s wholly owned pipeline. He highlights CYTOPE’s compelling preclinical evidence in pTDP-43, noting that it meaningfully reduces toxic aggregates and corrects abnormal RNA splicing in ALS models, while safely accessing the cytosol through a non-disruptive endosomal escape mechanism. Fein also emphasizes the modular design of CYTOPE, which can be adapted to antibodies, ASOs, and siRNAs, broadening its potential to other intracellular proteinopathies like α-synuclein and tau. On PRX012-TfR, he sees the transferrin receptor–based brain shuttle as a way to deepen amyloid-β clearance while limiting ARIA risk, positioning the program competitively in the Alzheimer’s landscape; accordingly, he reiterates a Buy rating and maintains his $30 price target. According to TipRanks, Fein is a 5-star analyst with an average return of 27.0% and a 57.03% success rate. Fein covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Palvella Therapeutics, and Denali Therapeutics. In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $20.00 price target. ### Related Stocks - [PRTA.US](https://longbridge.com/en/quote/PRTA.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) - [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md) - [DNLI.US](https://longbridge.com/en/quote/DNLI.US.md) ## Related News & Research - [Prothena (PRTA) Expected to Announce Quarterly Earnings on Monday](https://longbridge.com/en/news/293914353.md) - [Analyst Reiterates Buy on Prothena, Maintains $30 Price Target on Differentiated TTR-Depleter Opportunity](https://longbridge.com/en/news/293757628.md) - [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md) - [Generic drug sector seeks policy fixes after Trump tariff threat](https://longbridge.com/en/news/293501714.md) - [Trump Says US To Exempt Import Tariff On Generic Drugs For Two Years](https://longbridge.com/en/news/293481843.md)